NASDAQ:CYTK - Cytokinetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.55
  • Forecasted Upside: 29.50 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$39.03
▼ -1.87 (-4.57%)

This chart shows the closing price for CYTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytokinetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

Analyst Price Target is $50.55
▲ +29.50% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $50.55, with a high forecast of $75.00 and a low forecast of $36.00. The average price target represents a 29.50% upside from the last price of $39.03.

This chart shows the closing price for CYTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in Cytokinetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/4/2021HC WainwrightBoost Price TargetPositive ➝ Buy$58.00 ➝ $62.00High
11/4/2021JMP SecuritiesReiterated RatingBuyHigh
10/12/2021Cantor FitzgeraldBoost Price TargetOverweight$48.00 ➝ $57.00Low
10/8/2021HC WainwrightReiterated RatingBuy$58.00Medium
10/8/2021Morgan StanleyBoost Price TargetOverweight$38.00 ➝ $45.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$75.00High
9/7/2021BarclaysBoost Price TargetOverweight$40.00 ➝ $45.00High
8/9/2021Piper SandlerLower Price TargetOverweight$42.00 ➝ $40.00Low
8/6/2021HC WainwrightBoost Price TargetBuy$53.00 ➝ $58.00High
7/20/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$35.00 ➝ $48.00High
7/20/2021BarclaysBoost Price TargetOverweight$28.00 ➝ $40.00High
7/19/2021JMP SecuritiesBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $44.00High
7/19/2021Raymond JamesBoost Price TargetOutperform$37.00 ➝ $54.00High
7/19/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$25.00 ➝ $42.00High
7/19/2021HC WainwrightBoost Price TargetBuy$41.00 ➝ $53.00High
7/19/2021Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $48.00High
7/1/2021MizuhoInitiated CoverageBuy$36.00Low
5/11/2021MizuhoBoost Price TargetBuy$26.00 ➝ $36.00Medium
4/19/2021Morgan StanleyBoost Price TargetOverweight$24.00 ➝ $35.00Low
3/11/2021Wolfe ResearchInitiated CoverageOutperform$50.00High
2/18/2021BarclaysInitiated CoverageOverweight$28.00High
1/20/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $41.00High
12/16/2020Morgan StanleyBoost Price TargetOverweight$22.00 ➝ $24.00Low
12/14/2020MizuhoLower Price TargetBuy$31.00 ➝ $26.00High
11/24/2020Raymond JamesReiterated RatingBuyHigh
11/23/2020HC WainwrightLower Price TargetBuy$43.00 ➝ $22.00High
11/16/2020Needham & Company LLCReiterated RatingBuy$33.00Medium
11/16/2020Morgan StanleyLower Price TargetOverweight$24.00 ➝ $22.00High
10/28/2020The Goldman Sachs GroupInitiated CoverageNeutral$16.00Low
10/12/2020Morgan StanleyLower Price TargetOverweight$35.00 ➝ $24.00Low
10/8/2020HC WainwrightLower Price TargetPositive ➝ Buy$59.00 ➝ $43.00High
10/6/2020Cantor FitzgeraldBoost Price TargetOverweight$41.00 ➝ $48.00Medium
7/23/2020Piper SandlerBoost Price TargetOverweight$33.00 ➝ $36.00Low
7/23/2020HC WainwrightBoost Price TargetBuy$38.00 ➝ $59.00Low
7/15/2020Cantor FitzgeraldBoost Price TargetOverweight$29.00 ➝ $41.00High
7/15/2020JMP SecuritiesBoost Price TargetOutperform$23.00 ➝ $29.00High
7/14/2020Needham & Company LLCBoost Price TargetBuy$34.00 ➝ $45.00High
7/14/2020Piper SandlerBoost Price Target$28.00 ➝ $33.00High
7/14/2020HC WainwrightBoost Price TargetBuy$35.00 ➝ $38.00High
7/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00High
7/7/2020Morgan StanleyBoost Price TargetOverweight$29.00 ➝ $35.00High
5/23/2020MizuhoInitiated CoverageBuy$31.00Low
5/12/2020Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $29.00Low
5/11/2020HC WainwrightBoost Price TargetPositive ➝ Buy$30.00 ➝ $35.00High
5/7/2020Needham & Company LLCReiterated RatingBuy$24.00Low
5/4/2020MizuhoInitiated CoverageBuy$31.00High
4/27/2020Morgan StanleyReiterated RatingBuy$25.00Low
4/24/2020HC WainwrightReiterated RatingBuyMedium
4/19/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
4/17/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $23.00High
4/14/2020HC WainwrightReiterated RatingBuy$30.00Medium
4/14/2020Needham & Company LLCReiterated RatingBuy$24.00Low
4/9/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$14.00 ➝ $25.00High
3/31/2020HC WainwrightReiterated RatingBuy$30.00High
3/4/2020Needham & Company LLCReiterated RatingBuy$24.00Medium
2/26/2020HC WainwrightReiterated RatingBuy$30.00Low
2/7/2020HC WainwrightReiterated RatingBuyHigh
11/1/2019Needham & Company LLCReiterated RatingBuy$24.00High
10/4/2019Needham & Company LLCReiterated RatingBuy$16.00Low
10/4/2019HC WainwrightReiterated RatingBuy$26.00Medium
9/16/2019Piper Jaffray CompaniesReiterated RatingOverweight$14.00 ➝ $20.00High
9/13/2019JMP SecuritiesSet Price TargetBuy$23.00Medium
9/6/2019Cantor FitzgeraldReiterated RatingOverweight$14.00 ➝ $20.00Medium
8/9/2019Needham & Company LLCSet Price TargetBuy$16.00Medium
8/9/2019Morgan StanleySet Price TargetHold$16.00Medium
7/15/2019Morgan StanleySet Price TargetHold$11.00High
7/15/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00High
5/10/2019Cantor FitzgeraldReiterated RatingBuy$14.00Medium
5/6/2019HC WainwrightBoost Price TargetBuy$21.00 ➝ $26.00Medium
4/23/2019HC WainwrightSet Price TargetBuy$21.00High
3/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$12.00 ➝ $13.00High
3/19/2019HC WainwrightReiterated RatingBuy$21.00High
1/22/2019HC WainwrightReiterated RatingBuy$21.00Medium
12/5/2018HC WainwrightSet Price TargetBuy$21.00Low
12/5/2018Cantor FitzgeraldReiterated RatingBuy$14.00Low
11/27/2018HC WainwrightReiterated RatingBuy$21.00Low
11/2/2018HC WainwrightSet Price TargetBuy$21.00High
11/2/2018Cantor FitzgeraldSet Price TargetBuy$14.00High
10/17/2018HC WainwrightSet Price TargetBuy$21.00High
10/17/2018Cantor FitzgeraldSet Price TargetBuy$14.00High
10/5/2018HC WainwrightLower Price TargetBuy ➝ Buy$24.00 ➝ $21.00Low
10/5/2018Morgan StanleySet Price TargetHold$10.00High
10/3/2018Cantor FitzgeraldReiterated RatingBuy$14.00High
9/20/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$14.00High
9/10/2018Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$10.00Medium
8/1/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$18.00 ➝ $9.00High
7/27/2018HC WainwrightSet Price TargetBuy$24.00High
6/18/2018HC WainwrightBoost Price TargetBuy$24.00High
6/18/2018Piper Jaffray CompaniesLower Price TargetOverweight$13.00High
6/17/2018Cantor FitzgeraldReiterated RatingHold$10.00High
4/27/2018HC WainwrightReiterated RatingBuy$20.00High
4/24/2018Cantor FitzgeraldSet Price TargetHold$10.00Low
2/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $18.00High
2/20/2018CowenReiterated RatingBuy$11.00Medium
2/12/2018Cantor FitzgeraldSet Price TargetHold$10.00Low
1/19/2018HC WainwrightSet Price TargetBuy$20.00High
1/17/2018Cantor FitzgeraldReiterated RatingHold$10.00Low
11/29/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00Low
11/22/2017Morgan StanleyReiterated RatingOverweight ➝ Overweight$25.00 ➝ $17.00N/A
11/22/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$21.00 ➝ $10.00N/A
11/21/2017JMP SecuritiesReiterated RatingOutperform$17.00 ➝ $13.00N/A
11/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$18.00N/A
11/21/2017Needham & Company LLCDowngradeStrong-Buy ➝ Buy$22.00 ➝ $12.00N/A
11/21/2017HC WainwrightLower Price TargetBuy ➝ Buy$26.00 ➝ $17.00N/A
10/29/2017Needham & Company LLCReiterated RatingBuy$22.00N/A
10/27/2017HC WainwrightReiterated RatingBuy$26.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$24.00 ➝ $25.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$24.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$21.00Medium
9/20/2017HC WainwrightReiterated RatingBuy$26.00Low
9/18/2017Cantor FitzgeraldReiterated RatingBuy$21.00Low
9/17/2017Needham & Company LLCReiterated RatingBuy$22.00Low
8/4/2017CowenReiterated RatingBuy$19.00Low
8/3/2017HC WainwrightSet Price TargetBuy$26.00High
7/31/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$24.00High
5/19/2017Cantor FitzgeraldReiterated RatingOverweightMedium
4/29/2017CowenReiterated RatingOutperform$17.00 ➝ $19.00Low
4/25/2017HC WainwrightReiterated RatingBuy$25.00Low
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00Medium
3/13/2017HC WainwrightReiterated RatingBuyLow
3/8/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$25.00High
2/17/2017Cantor FitzgeraldReiterated RatingOverweight$21.00N/A
2/17/2017FBR & Co.Reiterated RatingOutperform$24.00N/A
2/17/2017Needham & Company LLCReiterated RatingStrong-Buy$22.00N/A
2/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/A
2/6/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$17.00 ➝ $22.00N/A
2/4/2017FBR & Co.Set Price TargetBuy$24.00N/A
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$21.00N/A
12/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/A
12/12/2016FBR & Co.Set Price TargetBuy$24.00N/A
12/1/2016FBR & Co.Reiterated RatingBuyN/A
12/1/2016JMP SecuritiesReiterated RatingBuyN/A
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/1/2021
  • 5 very positive mentions
  • 21 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
7/31/2021
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/30/2021
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 9 very positive mentions
  • 19 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 9 very positive mentions
  • 19 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Cytokinetics logo
Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $39.03
Low: $38.10
High: $40.89

50 Day Range

MA: $37.18
Low: $32.43
High: $41.73

52 Week Range

Now: $39.03
Low: $16.05
High: $42.87

Volume

504,515 shs

Average Volume

1,136,693 shs

Market Capitalization

$3.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?

The following equities research analysts have issued research reports on Cytokinetics in the last twelve months: Barclays PLC, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Mizuho, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for CYTK.

What is the current price target for Cytokinetics?

11 Wall Street analysts have set twelve-month price targets for Cytokinetics in the last year. Their average twelve-month price target is $50.55, suggesting a possible upside of 29.5%. Jefferies Financial Group Inc. has the highest price target set, predicting CYTK will reach $75.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $36.00 for Cytokinetics in the next year.
View the latest price targets for CYTK.

What is the current consensus analyst rating for Cytokinetics?

Cytokinetics currently has 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYTK will outperform the market and that investors should add to their positions of Cytokinetics.
View the latest ratings for CYTK.

How do I contact Cytokinetics' investor relations team?

Cytokinetics' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 624-3000 and its investor relations email address is [email protected] The official website for Cytokinetics is www.cytokinetics.com.